CD4 and gastric cancer: Moreover, XHSG had significantly increased percentage of CD4 positive cells (43.7%) and CD8 positive cells (39.2%) than XHNSG (3.2% and 2.9%, respectively) (P < 1E − 4); while the percentage of CD4 positive cells and CD8 positive cells were higher in XNSG (54.2% and 29.7%, respectively) compared with XSG (2.9% and 1.4%, respectively) (P < 0.05) (Fig. 4m).The result verified the findings that GC patients with high TCR signaling are unlikely to benefit from XELOX, but instead respond to XELOX+ anti-HER2.